| Literature DB >> 17953766 |
Jean-Philippe Levesque-Sergerie1, Mathieu Duquette, Catherine Thibault, Louis Delbecchi, Nathalie Bissonnette.
Abstract
BACKGROUND: In functional genomics, transcript measurement is of fundamental importance. Quantitative reverse transcription polymerase chain reaction (qRT-PCR) assays are the most popular technology and depend on the initial molecular step, the reverse transcription (RT). This study provides a complex overview of the influence of elements such as RT systems, amount of background RNA, and transcript abundance on the efficiency of qRT-PCR. Using qRT-PCR, we compared the efficiency of some commonly used RT systems and measured the production of PCR-amplifiable products and the influence of PCR inhibitor contents.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17953766 PMCID: PMC2151766 DOI: 10.1186/1471-2199-8-93
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
Dynamic range of template RNA amount for the five commercial RT systems tested.
| Commercial name | Type of RTa | Dynamic range (ng) |
| Omniscript | ? | 50–2,000 |
| PowerScript | MMLV | 1,000–5,000 |
| Sensiscript | ? | < 50 |
| SuperScript II | MMLV | 1–5,000 |
| SuperScript III | MMLV | 0.01–5,000 |
aBoth the Omniscript and the Sensiscript RTases retain RNase H activity. They are different from the RTases of Moloney murine leukaemia virus (MMLV) or avian myeloblastosis virus (AMV) origin (Sensiscript and Omniscript reverse transcriptase handbook, Qiagen). The Sensiscript RTase is a recombinant heterodimeric enzyme expressed in E. coli. TheSuperScript II and SuperScript III RTases are an engineered version of MMLV RTase with reduced RNase H activity and increased thermal stability. The PowerScript RTase is a point mutant of MMLV RTase, which lacks the RNase H enzyme and retains wild-type polymerase activity, thus being able to synthesise longer cDNA fragments [35].
Figure 1Quantitative measurements of RT reactions performed with five commercial systems. Amounts equal to 1/10 (2 μl) of the undiluted RT samples were quantified by qPCR (two-step qRT-PCR). Data are reported as the number of amplifiable cDNA copies in RT reactions spiked with 1 fg (A) or 1 pg (B) EGFP-template mRNA. All RT systems were tested and all results are reported, except for the Omniscript system in the presence of low-abundance transcript (A), which was undetectable. All RT reactions were performed and quantified in triplicate for each amount of background RNA ranging from 10 ng to 2 μg. Absolute values of EGFP copy number are deduced from a standard curve (Supplementary Table S1a) established with a purified EGFP DNA fragment (Methods). Statistical analysis is presented in Supplementary Table S3. *Different from other RT systems within a different background RNA quantity (P < 0.05; Supplementary Table S3).
Detection yield, copy number and cycle threshold obtained in qPCR for the RT systems Sensiscript, Omniscript, and SuperScript II.
| Background RNA (ng) | 0 | 10 | 25 | 50 | 100 | 1000 | 2000 | |
| RT systemsa | Datab | |||||||
| DY (%) | 0.62 | 1.36 | 7.69 | 14.57 | 16.64 | 13.61 | 10.63 | |
| Low copy | copy num. ± SD | 2 ± 2 | 3 ± 4 | 20 ± 18 | 37 ± 11 | 43 ± 21 | 35 ± 19 | 27 ± 24 |
| (Ct ± SD) | (39.52 ± 0.68) | (39.28 ± 0.71) | (37.19 ± 2.45) | (35.35 ± 0.43) | (35.34 ± 0.72) | (35.61 ± 0.93) | (36.87 ± 2.71) | |
| High copy | DY (%) | 3.92 | 25.61 | 29.79 | 39.26 | 38.77 | 48.33 | 50.41 |
| copy num. ± SD | 10 068 ± 8880 | 65 700 ± 9128 | 76 433 ± 833 | 100 733 ± 18 034 | 99 467 ± 9 089 | 124 000 ± 21 071 | 129 333 ± 34 020 | |
| (Ct ± SD) | (30.6 ± 7.14) | (24.24 ± 0.21) | (24.02 ± 0.02) | (23.62 ± 0.28) | (23.64 ± 0.14) | (23.29 ± 0.29) | (23.67 ± 0.14) | |
| copy num. ± SD | 0 ± 0 | 73 ± 25 | 236 ± 37 | 691 ± 39 | 2 150 ± 806 | 26 395 ± 1 404 | 42 488 ± 6 724 | |
| (Ct ± SD) | (40 ± 0) | (32 ± 0.62) | (30.03 ± 0.3) | (28.21 ± 0.09) | (26.42 ± 0.58) | (22.22 ± 0.09) | (21.45 ± 0.26) | |
| Low copy | DY & copy num. | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| DY (%) | 0.00 | 0.00 | 0.00 | 0.24 | 2.16 | 38.46 | 38.56 | |
| High copy | copy num. ± SD | 0 ± 0 | 0 ± 0 | 9 ± 15 | 623 ± 368 | 5 548 ± 4 152 | 98 664 ± 5 062 | 98 927 ± 11 165 |
| (Ct ± SD) | (40 ± 0) | (40 ± 0) | (38.41 ± 2.75) | (30.73 ± 1.59) | (27.53 ± 2.1) | (22.44 ± 0.08) | (22.44 ± 0.17) | |
| copy num. ± % | primer dimer | primer dimer | primer dimer | primer dimer | primer dimer | primer dimer | primer dimer | |
| DY (%) | 19.80 | 49.43 | 70.14 | 66.30 | 81.33 | 102.44 | 97.38 | |
| Low copy | copy num. ± SD | 51 ± 44 | 127 ± 39 | 180 ± 18 | 170 ± 49 | 209 ± 12 | 263 ± 40 | 250 ± 106 |
| (Ct ± SD) | (34.05 ± 0.04) | (33.41 ± 0.51) | (32.72 ± 0.19) | (32.82 ± 0.42) | (32.47 ± 0.09) | (32.15 ± 0.21) | (32.32 ± 0.7) | |
| DY (%) | 13.30 | 22.33 | 16.69 | 18.86 | 27.31 | 31.33 | 36.81 | |
| High copy | copy num. ± SD | 34 127 ± 4 284 | 57 277 ± 5 106 | 42 814 ± 26,175 | 48 389 ± 24 717 | 70 062 ± 8 760 | 80 366 ± 19 132 | 94 447 ± 10 237 |
| (Ct ± SD) | (23.52 ± 0.19) | (22.75 ± 0.14) | (23.48 ± 1.19) | (23.18 ± 0.98) | (22.45 ± 0.19) | (22.28 ± 0.4) | (22 ± 0.16) | |
| copy num. ± SD | 5 ± 9 | 102 ± 48 | 351 ± 201 | 1 122 ± 608 | 2 401 ± 752 | 19 088 ± 3 540 | 22 758 ± 1 815 | |
| (Ct ± SD) | (38.79 ± 2.1) | (30.84 ± 1.17) | (28.6 ± 1.12) | (26.43 ± 0.91) | (24.95 ± 0.57) | (21.2 ± 0.35) | (20.86 ± 0.14) | |
aRT systems tested were Sensiscript. Omniscript. SuperScript II. SuperScript III. and PowerScript; low copy. RT samples spiked with 2.6 × 103 EGFP mRNA copies; high copy. RT samples spiked with 2.6 × 106 EGFP mRNA copies.
bDY (detection yield) was calculated using the equation described in Results and the copy number (num.) was derived from the calibration curve for a given cycle threshold value (CT) [see Additional file 2];SD. standard deviation.
Detection yield, copy number and cycle threshold obtained in qPCR for the commercial RT systems SuperScript III and PowerScript
| Background RNA (ng) | 0 | 10 | 25 | 50 | 100 | 1000 | 2000 | |
| RT systemsa | Datab | |||||||
| DY (%) | 3.75 | 6.30 | 2.90 | 2.49 | 4.07 | 20.37 | 12.37 | |
| Low copy | copy num. ± SD | 10 ± 5 | 16 ± 20 | 7 ± 3 | 6 ± 5 | 10 ± 1 | 52 ± 28 | 32 ± 6 |
| (Ct ± SD) | (36.61 ± 1.44) | (37.87 ± 1.13) | (36.65 ± 0.6) | (37.19 ± 1.21) | (36.06 ± 0.2) | (33.89 ± 0.98) | (34.41 ± 0.2) | |
| DY (%) | 4.48 | 6.81 | 7.82 | 13.78 | 20.11 | 36.31 | 34.48 | |
| High copy | copy num. ± SD | 11 503 ± 6 190 | 17479 ± 1 861 | 20 053 ± 1 168 | 35 342 ± 4 588 | 51 592 ± 2 574 | 93 150 ± 10 206 | 88 458 ± 6 161 |
| (Ct ± SD) | (26.28 ± 0.99) | (25.51 ± 0.11) | (25.21 ± 0.09) | (24.37 ± 0.2) | (23.8 ± 0.07) | (22.93 ± 0.16) | (23 ± 0.01) | |
| copy num. ± SD | 0 ± 0 | 26 ± 3 | 99 ± 12 | 142 ± 24 | 229 ± 31 | 1 653 ± N/A | 5 314 ± 1 090 | |
| (Ct ± SD) | (40 ± 0) | (33.27 ± 0.29) | (30.98 ± 0.16) | (30.35 ± 0.29) | (29.55 ± 0.22) | (26.22 ± N/A) | (24.29 ± 0.37) | |
| DY (%) | 1.21 | 3.97 | 5.12 | 3.61 | 3.61 | 17.67 | 8.23 | |
| Low copy | copy num. ± SD | 3 ± 1 | 10 ± 5 | 13 ± 3 | 9 ± 3 | 11 ± 5 | 45 ± 18 | 21 ± 5 |
| (Ct ± SD) | (38.34 ± 0.47) | (36.48 ± 0.9) | (35.99 ± 0.41) | (36.56 ± 0.58) | (36.35 ± 0.76) | (34.17 ± 0.75) | (35.27 ± 0.37) | |
| DY (%) | 9.29 | 12.89 | 23.99 | 18.69 | 27.28 | 54.55 | 59.43 | |
| High copy | copy num. ± SD | 23 837 ± 723 | 33 078 ± 4 291 | 61 560 ± 340320 | 47 944 ± 9 523 | 69 982 ± 20 743 | 139 950 ± 10 479 | 152 480 ± 9 523 |
| (Ct ± SD) | (6.01 ± 0.05) | (25.53 ± 0.2) | (24.72 ± 0.77) | (23.2 ± 0.09) | (24.42 ± 0.45) | (23.33 ± 0.12) | (23.2 ± 0.09) | |
| copy num. ± SD | 2 ± 1 | 31 ± 3 | 168 ± 16 | 35 ± 8 | 58 ± 40 | 2 440 ± 650 | 6 118 ± 308 | |
| (Ct ± SD) | (36.85 ± 1.26) | (32.47 ± 0.18) | (30 ± 0.11) | (32.29 ± 0.35) | (31.9 ± 1.39) | (26.07 ± 0.38) | (24.69 ± 0.07) | |
aRT systems tested were Sensiscript. Omniscript. SuperScript II. SuperScript III. and PowerScript; low copy. RT samples spiked with 2.6 × 103 EGFP mRNA copies; high copy. RT samples spiked with 2.6 × 106 EGFP mRNA copies.
bDY (detection yield) was calculated using the equation described in Results and the copy number (num.) was derived from the calibration curve for a given cycle threshold value (CT) [see Additional file 2];SD. standard deviation.
Figure 2Effect of RT reaction dilution on the measurements of PCR amplifiable . Quantitative PCR was performed in triplicate on undiluted and diluted (1:50) RT samples prepared with each of the five commercial RT systems. The same quantity of EGFP mRNA (0.1 pg) was used to spike RT reactions in the presence of different amounts (0 to 2,000 ng) of background RNA.
Inhibition effect of the RT contents of five commercial RT systems measured by qRT-PCR.
| 14.7 ± 6.1% | |||||||
| -3.393 | ± 0.030 | 97.13 | ± 5.00% | 0.9981 | ± 0.0016 | ||
| -3.464 | ± 0.041 | 94.42 | ± 1.53% | 0.9983 | ± 0.0017 | ||
| -3.519 | ± 0.089 | 92.45 | ± 3.12% | 0.9968 | ± 0.0029 | ||
| 31.2 ± 23.5% | |||||||
| -3.227 | ± 0.054 | 104.14 | ± 2.42% | 0.9958 | ± 0.0035 | ||
| -3.323 | ± 0.057 | 99.98 | ± 2.37% | 0.9957 | ± 0.0038 | ||
| -3.473 | ± 0.208 | 94.50 | ± 8.10% | 0.9969 | ± 0.0019 | ||
| 59.7 ± 6.8% | |||||||
| -2.862 | ± 0.109 | 123.79 | ± 6.95% | 0.9907 | ± 0.0029 | ||
| -3.004 | ± 0.122 | 115.50 | ± 6.93% | 0.9920 | ± 0.0013 | ||
| -3.303 | ± 0.121 | 100.99 | ± 5.26% | 0.9971 | ± 0.0034 | ||
| 79.3 ± 2.9% | |||||||
| -2.400 | ± 0.095 | 161.44 | ± 10.16% | 0.9830 | ± 0.0057 | ||
| -2.583 | ± 0.083 | 144.07 | ± 6.84% | 0.9898 | ± 0.0040 | ||
| -2.882 | ± 0.069 | 122.43 | ± 4.34% | 0.9980 | ± 0.0024 | ||
| 69.3 ± 2.1% | |||||||
| -2.568 | ± 0.063 | 145.27 | ± 5.49% | 0.9693 | ± 0.0113 | ||
| -2.759 | ± 0.168 | 131.12 | ± 12.38% | 0.9694 | ± 0.0038 | ||
| -3.203 | ± 0.141 | 105.50 | ± 6.71% | 0.9817 | ± 0.0167 | ||
aResults report the means of triplicate assays for each RT system.
bAmplification efficiency is calculated using the equation E% = (1 - 10(-1/slope)) × 100, where 100% PCR efficiency corresponds to a slope (Δ Ct) of -3.3; E and coefficient of correlation (R2) are derived from the slope of a sample's calibration curve; SD, standard deviation.
Figure 3Influence of the background RNA the on detection of . The high-abundance EGFP results were reported as 1 fg equivalent (i.e. divided by 1,000), whereas low-abundance EGFP results were uncorrected. Quantities of cDNA copies detected for GNPDA in total RNA (Table 2 and 3) were corrected for the amount of background RNA. Data for the SuperScript II, SuperScript III, Sensiscript, and PowerScript systems (panels A, B, C, and D, respectively) were plotted using the same scale for comparison purposes.